Adjacent Evidence Brief: Intermittent fasting

Research Synthesis: Intermittent fasting

Abstract

This synthesis tests the thesis that evidence for Intermittent fasting is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.

Evidence-honesty note: 14/19 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on Intermittent fasting across 19 included source papers and 1344 high-confidence extracted claims.

The evidence profile contains 5 direct clinical sources, 14 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with a high-density pairwise disagreement map across the evidence base.

No single positive outcome class dominates the retained corpus; null signals cluster in the cardiometabolic and contextual adjacent evidence outcome classes, and negative signals cluster in the cardiometabolic outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that Intermittent fasting remains a bounded evidence case: the retained direct, adjacent, and context evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

Methods

Review type and protocol

This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-intermittent_fasting-v06-DAILY-2026-07-03T04-07-41Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-03.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• intermittent fasting AND aging AND randomized trial
• time-restricted eating AND older adults
• alternate-day fasting AND metabolic health
• intermittent fasting AND longevity AND human
• time restricted feeding AND cardiometabolic AND trial
• early time-restricted feeding AND insulin sensitivity
• time-restricted eating AND lean mass AND trial
• intermittent fasting AND adherence AND adverse events
• periodic fasting AND inflammation AND human

Eligibility criteria

• Sources whose primary content addresses intermittent fasting.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 104 records in the receipt-candidate union, 44 were classified as source candidates and 19 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
source candidate union	104
Classified source candidates	44
No extractable claims	7
None-only claim binding	2
Mixed partial-or-none claim-binding candidates	29
Partial-only claim-binding candidates	9
Strict high-confidence sources	13
Admitted final sources	19

Exclusion reasons

• No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated risk_of_bias.json rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Evidence Landscape

Findings Map

Findings Map completeness note: all 19 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

Evidence domain	Source	Direction	Directness	Tier	Evidence role	Finding
Cardiometabolic	Breit 2025: Effects of 4:3 Intermittent Fasting on Eating Behaviors and Appetite Hormones: A Secondary Analysis of a 12-Month Behavioral Weight Loss Intervention	direction=unclear	directness=indirect	B2	outcome=Cardiometabolic; direction=unclear	finding=representative statistic P < 0.01; source-level statistic reported
Cardiometabolic	Couto-Alfonso 2026: Intermittent Fasting and Healthy Aging in Older Adults: A Systematic Review of Cardiometabolic, Mental Health and Cognitive Outcomes with a Network Meta-Analysis of Anthropometric Measures	direction=mixed	directness=review	B1	outcome=Cardiometabolic; direction=mixed	finding=representative statistic P = 0.001; source-level statistic reported
Cardiometabolic	Feehan 2023: Time-Restricted Fasting Improves Liver Steatosis in Non-Alcoholic Fatty Liver Disease—A Single Blinded Crossover Trial	direction=unclear	directness=indirect	B2	outcome=Cardiometabolic; direction=unclear	finding=representative statistic P = 0.038; source-level statistic reported
Cardiometabolic	He 2026: The effects of intermittent fasting on BMI, fasting blood glucose, and blood pressure in women with overweight or obesity: a systematic review and meta-analysis with dose–response relationships	direction=unclear	directness=review	B1	outcome=Cardiometabolic; direction=unclear	finding=representative statistic P = 0.0396; source-level statistic reported
Cardiometabolic	Jiao 2026: Optimal dosage of exercise combined with intermittent fasting for body composition and cardiometabolic health in adults: a systematic review and multilevel meta-analysis	direction=unclear	directness=review	B2	outcome=Cardiometabolic; direction=unclear	finding=representative statistic P < 0.01; source-level statistic reported
Cardiometabolic	Kender 2023: Six-month periodic fasting does not affect somatosensory nerve function in type 2 diabetes patients	direction=null	directness=indirect	B2	outcome=Cardiometabolic; direction=null	finding=representative statistic P = 0.04; source-level statistic reported
Cardiometabolic	Koh 2025: The Effectiveness of Time-Restricted Eating as an Intermittent Fasting Approach on Shift Workers’ Glucose Metabolism: A Systematic Review and Meta-Analysis	direction=unclear	directness=review	B2	outcome=Cardiometabolic; direction=unclear	finding=representative non-significant statistic P = 0.77; not treated as positive or negative directional support unless source direction is coded
Cardiometabolic	Kroeger 2018: Eating behavior traits of successful weight losers during 12 months of alternate-day fasting: An exploratory analysis of a randomized controlled trial.	direction=unclear	directness=direct	A1	outcome=Cardiometabolic; direction=unclear	finding=representative statistic P = 0.04; source-level statistic reported
Cardiometabolic	Martinez-Montoro 2025: Effect of a ketogenic diet, time-restricted eating, or alternate-day fasting on weight loss in adults with obesity: a randomized clinical trial	direction=null	directness=direct	A1	outcome=Cardiometabolic; direction=null	finding=218 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Mindikoglu 2020: Intermittent fasting from dawn to sunset for four consecutive weeks induces anticancer serum proteome response and improves metabolic syndrome	direction=positive	directness=indirect	B2	outcome=Biomarker/Adjacent Cardiometabolic; direction=positive	finding=representative statistic P < 0.0001; source-level statistic reported
Cardiometabolic	Monda 2026: Metabolic and Orexin-A Responses to Ketogenic Diet and Intermittent Fasting: A 12-Month Randomized Trial in Adults with Obesity	direction=negative	directness=direct	A1	outcome=Cardiometabolic; direction=negative	finding=representative statistic P = 0.004; source-level statistic reported
Cardiometabolic	Pascual 2023: A meta‐analysis comparing the effectiveness of alternate day fasting, the 5:2 diet, and time‐restricted eating for weight loss	direction=null	directness=indirect	B2	outcome=Cardiometabolic; direction=null	finding=representative non-significant statistic P = 0.37; not treated as positive or negative directional support unless source direction is coded
Cardiometabolic	Peters 2024: Twenty-Four Hour Glucose Profiles and Glycemic Variability during Intermittent Religious Dry Fasting and Time-Restricted Eating in Subjects without Diabetes: A Preliminary Study	direction=unclear	directness=indirect	B2	outcome=Cardiometabolic; direction=unclear	finding=representative statistic P = 0.013; source-level statistic reported
Cardiometabolic	Song 2025: Intermittent fasting improves metabolic outcomes in metabolic syndrome: a systematic review and meta-analysis with GRADE evaluation	direction=unclear	directness=review	B2	outcome=Cardiometabolic; direction=unclear	finding=representative statistic P = 0.001; source-level statistic reported
Cardiometabolic	Talebi 2023: The effects of intermittent fasting diet alone or in combination with probiotic supplementation in comparison with calorie-restricted diet on metabolic and hormonal profile in patients with polycystic ovary syndrome: study protocol for a randomized clinical trial	direction=null	directness=direct	A1	outcome=Cardiometabolic; direction=null	finding=16 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Xing 2026: Age-Specific Analysis of the Effects of Intermittent Fasting on Body Composition and Cardiometabolic Markers in Healthy Adults and Individuals with Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	direction=unclear	directness=review	B2	outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear	finding=representative statistic P < 0.001; source-level statistic reported
Contextual Adjacent Evidence	Huang 2021: An Intermittent Fasting Mimicking Nutrition Bar Extends Physiologic Ketosis in Time Restricted Eating: A Randomized, Controlled, Parallel-Arm Study	direction=null	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=null	finding=16 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Soliman 2022: Intermittent fasting and time-restricted eating role in dietary interventions and precision nutrition	direction=null	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=1 extracted claim(s); source-level direction is the coded finding
Safety and Comorbidity	Cuevas-Cervera 2022: The Effectiveness of Intermittent Fasting, Time Restricted Feeding, Caloric Restriction, a Ketogenic Diet and the Mediterranean Diet as Part of the Treatment Plan to Improve Health and Chronic Musculoskeletal Pain: A Systematic Review	direction=unclear	directness=review	B2	outcome=Safety and Comorbidity; direction=unclear	finding=representative statistic P = 0.025; source-level statistic reported

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Intermittent fasting / Cardiometabolic	n=16; claims=1290	significant source statistic in 13/16 sources; receipt-level direction coded unclear	4 direct; 6 indirect; 6 review	limited corpus depth in this outcome class
Intermittent fasting / Contextual Adjacent Evidence	n=2; claims=17	no extracted directional signal in 2/2 sources	1 direct; 1 indirect	limited corpus depth in this outcome class
Intermittent fasting / Safety and Comorbidity	n=1; claims=37	significant source statistic in 1/1 sources; receipt-level direction coded unclear	1 review	single-source slice; hypothesis-generating

Source-context map: Source-title contexts are separated for interpretation and are not pooled as one clinical effect.

• Aging and geroscience context: 1 sources; mixed signal in 1/1 sources.
• Dosing and pharmacokinetics context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.
• Oncology and cancer context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.

Cardiometabolic Outcomes

Cardiometabolic remains a separate Results slice for Intermittent fasting (n=16; claims=1290; significant source statistic in 13/16 sources; receipt-level direction coded unclear; 4 direct; 6 indirect; 6 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:

• Monda 2026 (Metabolic and Orexin-A Responses to Ketogenic Diet and Intermittent Fasting: A 12-Month Randomized Trial in Adults with; representative statistic p = 0.004; source-level statistic reported; outcome=Cardiometabolic; direction=negative; directness=direct; tier=A1).
• Kroeger 2018 (Eating behavior traits of successful weight losers during 12 months of alternate-day fasting: An exploratory analysis; representative statistic p = 0.04; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1).
• Couto-Alfonso 2026 (Intermittent Fasting and Healthy Aging in Older Adults: A Systematic Review of Cardiometabolic, Mental Health and; representative statistic p = 0.001; source-level statistic reported; outcome=Cardiometabolic; direction=mixed; directness=review; tier=B1).
• Mindikoglu 2020 (Intermittent fasting from dawn to sunset for four consecutive weeks induces anticancer serum proteome response and; representative statistic P < 0.0001; source-level statistic reported; outcome=Biomarker/Adjacent Cardiometabolic; direction=positive; directness=indirect; tier=B2).

Direction reconciliation: receipt-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

Contextual Adjacent Evidence Outcomes

Contextual Adjacent Evidence remains a separate Results slice for Intermittent fasting (n=2; claims=17; no extracted directional signal in 2/2 sources; 1 direct; 1 indirect; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:

• Huang 2021 (An Intermittent Fasting Mimicking Nutrition Bar Extends Physiologic Ketosis in Time Restricted Eating: A Randomized; 16 extracted claim(s); receipt-level direction is the coded finding; outcome=Contextual Adjacent Evidence; direction=null; directness=direct; tier=A1).
• Soliman 2022 (Intermittent fasting and time-restricted eating role in dietary interventions and precision nutrition; 1 extracted claim(s); receipt-level direction is the coded finding; outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2).

Safety and Comorbidity Outcomes

Safety and Comorbidity remains a separate Results slice for Intermittent fasting (n=1; claims=37; significant source statistic in 1/1 sources; receipt-level direction coded unclear; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:

• Cuevas-Cervera 2022 (The Effectiveness of Intermittent Fasting, Time Restricted Feeding, Caloric Restriction, a Ketogenic Diet and the; representative statistic p = 0.025; source-level statistic reported; outcome=Safety and Comorbidity; direction=unclear; directness=review; tier=B2).

For Intermittent fasting, the final interpretation is deliberately tiered: the retained direct, adjacent, and context evidence profile defines a bounded evidence rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general efficacy endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent/context evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support Intermittent fasting as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone longevity intervention with proven hard clinical-outcome effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 19 included sources on Intermittent Fasting across 3 outcome classes and 72 cross-study disagreements. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

Across 19 curated reference papers, the evidence base for intermittent fasting shows a context-dependent profile. Negative signals appear in: cardiometabolic. Null findings dominate: cardiometabolic, contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The broad aging-related case for intermittent fasting as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the null vs negative between Talebi 2023 and Monda 2026 on cardiometabolic (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Couto-Alfonso 2026, He 2026) emphasize convergent signals on Intermittent Fasting. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
cardiometabolic	4	12	mixed, negative, null, unclear	conflict-resolution gap
safety and comorbidity	0	1	unclear	direct interventional hard-endpoint gap
contextual adjacent evidence	1	1	null	replication gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	cardiometabolic: conflict-resolution gap	4 direct and 12 indirect sources; direction profile: mixed, negative, null, unclear
P2	safety and comorbidity: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: unclear
P3	contextual adjacent evidence: replication gap	1 direct and 1 indirect sources; direction profile: null

Next-Study Design Recommendation

The next high-yield study for Intermittent Fasting should target the cardiometabolic evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 100 participants per arm, a priority population of the same population type as the strongest direct source cluster, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Martinez-Montoro 2025; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null.
• Monda 2026; tier=A1; directness=direct; endpoint=cardiometabolic; direction=negative; representative statistic=P < 0.001.
• Huang 2021; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null.
• Talebi 2023; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null.
• Kroeger 2018; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.03.
• Couto-Alfonso 2026; tier=B1; directness=review; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.0001.
• He 2026; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.00.
• Mindikoglu 2020; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.0001.
• Xing 2026; tier=B2; directness=review; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.001.
• Kender 2023; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.001.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Martinez-Montoro 2025: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=218.
• Monda 2026: outcome=cardiometabolic; directness=direct; tier=A1; direction=negative; claims=92.
• Huang 2021: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=16.
• Talebi 2023: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=16.
• Kroeger 2018: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=9.
• Couto-Alfonso 2026: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=275.
• He 2026: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=64.
• Mindikoglu 2020: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=97.
• Xing 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=89.
• Kender 2023: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=84.
• Jiao 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=77.
• Breit 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=55.
• Song 2025: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=55.
• Koh 2025: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=49.
• Peters 2024: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=48.
• Feehan 2023: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=38.
• Cuevas-Cervera 2022: outcome=safety comorbidity; directness=review; tier=B2; direction=unclear; claims=37.
• Pascual 2023: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=24.
• Soliman 2022: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=1.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 4 null vs negative: Talebi 2023 vs Monda 2026; Monda 2026 (negative on cardiometabolic) vs Talebi 2023 (null on cardiometabolic) — partial conflict
• Severity 4 null vs negative: Martinez-Montoro 2025 vs Monda 2026; Monda 2026 (negative on cardiometabolic) vs Martinez-Montoro 2025 (null on cardiometabolic) — partial conflict
• Severity 3 indirectness gap: Pascual 2023 vs Talebi 2023; Talebi 2023 (direct, A1) vs Pascual 2023 (indirect) on cardiometabolic — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Pascual 2023 vs Martinez-Montoro 2025; Martinez-Montoro 2025 (direct, A1) vs Pascual 2023 (indirect) on cardiometabolic — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Pascual 2023 vs Monda 2026; Monda 2026 (direct, A1) vs Pascual 2023 (indirect) on cardiometabolic — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Pascual 2023 vs Kroeger 2018; Kroeger 2018 (direct, A1) vs Pascual 2023 (indirect) on cardiometabolic — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Kender 2023 vs Talebi 2023; Talebi 2023 (direct, A1) vs Kender 2023 (indirect) on cardiometabolic — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Kender 2023 vs Martinez-Montoro 2025; Martinez-Montoro 2025 (direct, A1) vs Kender 2023 (indirect) on cardiometabolic — direct vs indirect must be kept separate

Limitations

The principal limitation is evidence-role imbalance. The retained corpus contains 5 direct clinical sources, 14 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, which means causal interpretation depends on how much weight is assigned to each evidence tier.

A second limitation is endpoint heterogeneity. Study-level signals span no dominant outcome class, the cardiometabolic and contextual adjacent evidence outcome classes, the cardiometabolic outcome class, and the cardiometabolic outcome class; these domains cannot be pooled narratively without losing clinically relevant differences in measurement, population, and study design.

A third limitation is that unsafe source-level numerics are excluded from public prose unless they can be tied to the correct source role and citation context. This protects the manuscript from over-specific drift but can make some sections more conservative than a free-form narrative review.

Conclusion

For Intermittent fasting, the final interpretation is deliberately tiered: the retained direct, adjacent, and context evidence profile defines a bounded evidence rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general efficacy endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent/context evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. Pending further trials, the intervention should not be used off-label for broad aging-related prevention claims outside clinical-trial settings given current evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

References

• Couto-Alfonso 2026. Intermittent Fasting and Healthy Aging in Older Adults: A Systematic Review of Cardiometabolic, Mental Health and Cognitive Outcomes with a Network Meta-Analysis of Anthropometric Measures. Nutrients, 2026. DOI: 10.3390/nu18091450 PMID: 42124054.
• Martinez-Montoro 2025. Effect of a ketogenic diet, time-restricted eating, or alternate-day fasting on weight loss in adults with obesity: a randomized clinical trial. BMC Medicine, 2025. DOI: 10.1186/s12916-025-04182-z PMID: 40598397.
• Mindikoglu 2020. Intermittent fasting from dawn to sunset for four consecutive weeks induces anticancer serum proteome response and improves metabolic syndrome. Scientific Reports, 2020. DOI: 10.1038/s41598-020-73767-w PMID: 33110154.
• Monda 2026. Metabolic and Orexin-A Responses to Ketogenic Diet and Intermittent Fasting: A 12-Month Randomized Trial in Adults with Obesity. Nutrients, 2026. DOI: 10.3390/nu18020238 PMID: 41599851.
• Xing 2026. Age-Specific Analysis of the Effects of Intermittent Fasting on Body Composition and Cardiometabolic Markers in Healthy Adults and Individuals with Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 2026. DOI: 10.3390/nu18111799 PMID: 42280443.
• Kender 2023. Six-month periodic fasting does not affect somatosensory nerve function in type 2 diabetes patients. Frontiers in Endocrinology, 2023. DOI: 10.3389/fendo.2023.1143799 PMID: 37251671.
• Jiao 2026. Optimal dosage of exercise combined with intermittent fasting for body composition and cardiometabolic health in adults: a systematic review and multilevel meta-analysis. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1772836 PMID: 41883415.
• He 2026. The effects of intermittent fasting on BMI, fasting blood glucose, and blood pressure in women with overweight or obesity: a systematic review and meta-analysis with dose–response relationships. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1818813 PMID: 42221756.
• Breit 2025. Effects of 4:3 Intermittent Fasting on Eating Behaviors and Appetite Hormones: A Secondary Analysis of a 12-Month Behavioral Weight Loss Intervention. Nutrients, 2025. DOI: 10.3390/nu17142385 PMID: 40733010.
• Song 2025. Intermittent fasting improves metabolic outcomes in metabolic syndrome: a systematic review and meta-analysis with GRADE evaluation. Frontiers in Nutrition, 2025. DOI: 10.3389/fnut.2025.1664811 PMID: 41459076.
• Koh 2025. The Effectiveness of Time-Restricted Eating as an Intermittent Fasting Approach on Shift Workers’ Glucose Metabolism: A Systematic Review and Meta-Analysis. Nutrients, 2025. DOI: 10.3390/nu17101689 PMID: 40431429.
• Peters 2024. Twenty-Four Hour Glucose Profiles and Glycemic Variability during Intermittent Religious Dry Fasting and Time-Restricted Eating in Subjects without Diabetes: A Preliminary Study. Nutrients, 2024. DOI: 10.3390/nu16162663 PMID: 39203800.
• Feehan 2023. Time-Restricted Fasting Improves Liver Steatosis in Non-Alcoholic Fatty Liver Disease—A Single Blinded Crossover Trial. Nutrients, 2023. DOI: 10.3390/nu15234870 PMID: 38068729.
• Cuevas-Cervera 2022. The Effectiveness of Intermittent Fasting, Time Restricted Feeding, Caloric Restriction, a Ketogenic Diet and the Mediterranean Diet as Part of the Treatment Plan to Improve Health and Chronic Musculoskeletal Pain: A Systematic Review. International Journal of Environmental Research and Public Health, 2022. DOI: 10.3390/ijerph19116698 PMID: 35682282.
• Pascual 2023. A meta‐analysis comparing the effectiveness of alternate day fasting, the 5:2 diet, and time‐restricted eating for weight loss. Obesity (Silver Spring, Md.), 2023. DOI: 10.1002/oby.23568 PMID: 36349432.
• Talebi 2023. The effects of intermittent fasting diet alone or in combination with probiotic supplementation in comparison with calorie-restricted diet on metabolic and hormonal profile in patients with polycystic ovary syndrome: study protocol for a randomized clinical trial. Trials, 2023. DOI: 10.1186/s13063-023-07691-5 PMID: 37880791.
• Huang 2021. An Intermittent Fasting Mimicking Nutrition Bar Extends Physiologic Ketosis in Time Restricted Eating: A Randomized, Controlled, Parallel-Arm Study. Nutrients, 2021. DOI: 10.3390/nu13051523 PMID: 33946428.
• Kroeger 2018. Eating behavior traits of successful weight losers during 12 months of alternate-day fasting: An exploratory analysis of a randomized controlled trial. Nutr Health, 2018. DOI: 10.1177/0260106017753487 PMID: 29353535.
• Soliman 2022. Intermittent fasting and time-restricted eating role in dietary interventions and precision nutrition. Frontiers in Public Health, 2022. DOI: 10.3389/fpubh.2022.1017254 PMID: 36388372.

Background References

Canonical reference values and methodological references cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).